Lysophosphatidic acid acyltransferase beta (LPAAT-β) is an enzyme that produces phosphatidic acid, which functions as a cofactor in cell survival and proliferative pathways. Phosphatidic acid contributes to the translocation and full activation of Raf and mTOR. While the role of phospholipase D and diacylglycerol kinase in generating phosphatidic acid involved in cellular signaling has been studied, little is known about the role of LPAAT-β. In this report, Springett et al. examine the expression of LPAAT-β protein in ovarian and endometrial cancer tissue arrays using immunohistochemistry. They found that elevated expression of LPAAT-β correlated with aggressive tumor histology and was associated with reduced overall survival in ovarian cancer and shorter time to progression in ovarian and endometrial cancer. Selective inhibition of LPAAT-β with small molecule inhibitors that are aryldiaminotriazines induces apoptosis in human ovarian and endometrial cancer cell lines in vitro at nanomolar concentrations. These compounds were able to prolong the survival of mice bearing a human ovarian cancer peritoneal carcinomatosis model. More than 22,000 women die from ovarian and endometrial cancer every year and improvements in the treatment of these cancers are needed. LPAAT-β is identified in this report as a potential new prognostic marker and therapeutic target in gynecologic cancers. For details, see the article by Springett et al. on page 9415 of this issue.